NewsRoom Articles - Page 208 of 225

FridaySep 25, 2020 1:15 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, a novel DNA binding agent, was 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Industry reports estimate that the global brain…

FridaySep 25, 2020 12:00 pm

Researchers Invent Tiny Robot to Change the Future of Surgery

Researchers from the Georgia Institute of Technology and Ohio State University have discovered a way to send soft tiny robots into humans. This may open the door for ways to deliver treatments for various conditions ranging from aortic artery blockages to colon polyps as well as less invasive surgical procedures. The comprehensive study, which uses origami, an ancient Japanese practice, was published in the Proceedings of the National Academy of Sciences on September 14. Renee Zhao, an assistant professor of mechanical and aerospace engineering at Ohio State University and the co-author of the paper, stated that using this method, doctors…

FridaySep 25, 2020 11:49 am

180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021

Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027 Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade The number of conditions with chronic inflammation is expected to increase persistently over the next 30 years in the United States. 180 Life Sciences is in the process of being acquired by KBLM Merger Corp. and the acquisition is expected to finalize in Q4 2020 Clinical-stage biotechnology company 180 Life Sciences Corp. is leading the way with research into the world’s most…

ThursdaySep 24, 2020 3:30 pm

Innovative Team Discovers N95 Masks Can Be Recharged to Restore Their Efficacy

Since the coronavirus crisis was declared a pandemic, N95 masks, which are a design of personal protective equipment have been in short supply. N95 masks as well as other masks used in the medical field use two filtration methods, electrostatic filtering and mechanical filtering using mask fibers. Electrostatic filtering uses stationary electric charges to attract and catch minute 0.3-micron particles such as fluid droplets that may contain viruses. N95 masks are also only for single day use as they become less effective at filtering out minute particles once the electrostatic charges that are present in the mask leak into the…

ThursdaySep 24, 2020 2:08 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Inks Major Contract; Skyline Medical Seals STREAMWAY Deal

POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition Founder calls contract “major milestone,” validation of move into new facility POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization Soluble Biotech, a division of Predictive Oncology (NASDAQ: POAI), has finalized its first substantial contract with a pharmaceutical company since being acquired by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. The contract calls for Soluble Biotech’s expertise in protein expression and solubility studies. “Our first…

ThursdaySep 24, 2020 1:45 pm

Scientists Develop Human Retinas in a Dish

A team of scientists from the Institute for Molecular and Clinical Ophthalmology Basel (“IOB”) that was led by Botond Roska, in collaboration with the Novartis Institutes for BioMedical Research, have created indistinguishable replicas of human retinas in culture. These will be used to help find the specific cell types that are affected by genetic eye ailments. This project, which took 6 years, will significantly speed up the process of developing new therapies for eye ailments. The paper’s principal author, who is also a senior researcher in the IOB Human Retinal Circuit Group, Cameron Cowan, says that the research sheds light…

WednesdaySep 23, 2020 3:15 pm

Harvard Professor Launching Nasal Hygiene Mist Developed to Reduce Coronavirus Transmission

David A. Edwards, a professor of Biomedical Engineering at Harvard, is set to launch a new product that he developed, this fall. He claims that the product reduces almost 100% of particles that are present in exhaled air. This will help reduce the transmission of SARS-CoV-2 both out of and into the lungs while breathing. This would mean that the risk of contracting COVID-19 would significantly decrease, especially for frontline workers, when it is used in combination with other Personal Protective Equipment like face masks. The product is known as FEND and has been produced by Sensory Cloud, a tech…

WednesdaySep 23, 2020 2:00 pm

Federal Government Announces COVID-19 Vaccine Distribution Plan

On Wednesday of last week, the Trump administration announced their plan to distribute a coronavirus vaccine, free of charge, once it has been approved for use. The plan focuses on targeted groups then expands as the supply of the vaccine grows. The government released a phased distribution using a contract that was awarded to McKesson earlier in August of this year. The first recipients of the vaccine could be: Healthcare workers who are likely to be exposed to the virus or those that treat and care for people who have COVID-19. Other essential workers Individuals who are at an increased…

WednesdaySep 23, 2020 12:54 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Mines Investment-building Opportunity for Brain Tumor-Targeting Drug Candidate at Annual Conference

CNS Pharmaceuticals is a clinical-stage biotechnology company developing therapies to combat aggressive cancers of the brain and central nervous system The company will be applying for approval to launch Phase II trials in the first quarter of 2021 for its leading drug candidate, Berubicin, which targets glioblastoma multiforme (“GBM”) brain cancer CNS Pharmaceuticals CEO addressed the company’s achievements and its vision for Berubicin development during the recent 22nd annual Global Investment Conference sponsored by H.C. Wainwright & Co. C. Wainwright is a full-service investment bank focused on capital markets and equity research in market sectors that hinge on industries encompassing…

TuesdaySep 22, 2020 3:00 pm

EU Announces Plans to Form Biomedical Research Agency

Ursula von der Leyen, the European Commission president, announced plans for the European Union (“EU”) to play a much greater role in the health sector. The EU plans to form a new agency for biomedical research, which will be modeled on the United States Biomedical Advanced Research and Development Authority (“BARDA”). The agency will help reinforce the European Center for Disease prevention and Control and the European Medicines Agency. The EU BARDA will also support the European Union’s readiness and capacity to counter cross-border emergencies and threats, whether they were deliberate or natural. The EU BARDA is seen as a…